# BRICKET (NCT06578559)

> Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06578559
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Conditions: Colorectal Cancer
- Interventions: Cetuximab; Encorafenib
- Enrollment: 16
- Primary outcome: Objective Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 11

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=bricket-nct06578559

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06578559", "email": "<work email>"}; the inbox owner confirms by the emailed link.